Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...
Patients being treated with dual-antiplatelet therapy (DAPT) consisting of clopidogrel plus aspirin following atrial septal defect (ASD) closure can safely discontinue clopidogrel after 3 months ...
Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...
The National Institute for Clinical Excellence is examining endovascular closure of atrial septal defect and will publish guidance on its safety and efficacy to the NHS in England, Wales and Scotland.
Debate: My Patient has a Blood Pressure of 150/90 Despite 2 Maximally Dosed Medications – Time for a Third Medication! Receive the the latest news, research, and presentations from major meetings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results